Interview: CellCentric Prostate Cancer Drug Promises Much

The Cambridge-based company's CEO Will West tells Scrip that CCS1477 has shown a lot of potential for patients with late-stage prostate cancer who are resistant to second-line anti-androgen drugs like Zytiga and Xtandi and the $26m it has just raised will help fund development of the epigenetic therapy up to Phase IIb.

Prostate cancer
CellCentric says it has a first-in-class prostate cancer therapy • Source: Shutterstock

Having investigated around 60 potential epigenetic-related drug targets, the UK's CellCentric Ltd. believes it has found one that is a first-in-class candidate for treatment-resistant prostate cancer and is heading to the clinic with $26m in new funds.

The Cambridge-headquartered privately held biotech has raised all the cash from one of its existing backers - Morningside Venture Investments...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

 

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

Lilly’s Verzenio Scores First OS Improvement In Key Breast Cancer Setting In Decades

 

The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

More from Therapy Areas

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Psychedelic Drug Development Shows Promise, But Market Path Remains Steep

 

With late-stage trials advancing and regulatory guidance in place, psychedelic medicines are nearing a pivotal moment in their path to market. Success will hinge on overcoming clinical, logistical and commercial challenges.

Vor Unveils Positive IgAN Data For Telitacicept, But Prioritizes gMG, Sjögren’s

 

A China-only Phase III study for the anti-BAFF/APRIL fusion protein marks the latest positive dataset for the drug, which Vor licensed from China-based RemeGen in June.